Phase 4
N=79
Liposomal Bupivacaine Interscalene Blocks for Rotator Cuff Repair
Acute Pain
Bottom Line
View on ClinicalTrials.gov: NCT03587584 ↗Enrolled (actual)
79
Serious AEs
0.0%
Results posted
Jul 2022
Primary outcome: Primary: Total Intraoperative Opioids Used — .1; .1; 30; 30 mg
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- liposomal bupivacaine (Drug); Bupivacaine (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- University of Minnesota
- Primary completion
- May 2021
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Total Intraoperative Opioids Used |
.1; .1; 30; 30; 0; 0 | — |
Summary
The purpose of this study is to compare pain control after arthroscopic rotator cuff repair surgery using either liposomal bupivacaine or bupivacaine when injected in an interscalene block. Both medications, liposomal bupivacaine and bupivacaine, are standard of care in these types of surgeries.
Eligibility Criteria
Inclusion Criteria
- Adult patients aged greater than 18 years of age that are undergoing arthroscopic rotator cuff surgery
Exclusion Criteria
- Patients with allergy to local anesthetics
- Patients with daily use of opioids for more than 3 weeks prior to surgery
- Patients who refuse
- Patients with coagulopathy
- Patients who are non-english speaking
- Patients who do not have access to a telephone
Data sourced from ClinicalTrials.gov (NCT03587584). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.